META060 attenuates TNF-α-activated inflammation, endothelial-monocyte interactions, and matrix metalloproteinase-9 expression, and inhibits NF-κB and AP-1 in THP-1 monocytes

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 130-136

  Desai, Anuradha ^a   Darland, Gary ^a   Bland, Jeffrey S ^a   Tripp, Matthew L ^a   Konda, Veera R ^a  

^a Metagenics Inc   (United States)

Author keywords

Atherosclerosis; Endothelial function; Hops; META060; MMP 9; NF B; TNF

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; META 060; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; RANTES; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; HOPS; HUMAN; HUMAN CELL; IMMUNOASSAY; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; ZYMOGRAPHY;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CELL ADHESION; CELL COMMUNICATION; CELL LINE; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; HUMULUS; INFLAMMATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASE 9; MONOCYTES; NF-KAPPA B; PLANT EXTRACTS; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863089987     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.05.004     Document Type: Article

References (30)

1. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83:456S-460S.
2. Ellingsen I., Hjerkinn E.M., Seljeflot I., Arnesen H., Tonstad S. Consumption of fruit and berries is inversely associated with carotid atherosclerosis in elderly men. Br J Nutr 2008, 99:674-681.
3. Steffen L.M., Jacobs D.R., Stevens J., Shahar E., Carithers T., Folsom A.R. Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Am J Clin Nutr 2003, 78:383-390.
4. Miura Y., Chiba T., Tomita I., Koizumi H., Miura S., Umegaki K., et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 2001, 131:27-32.
5. Ahmad M., Theofanidis P., Medford R.M. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. J Biol Chem 1998, 273:4616-4621.
6. Cullen J.P., Morrow D., Jin Y., von Offenberg Sweeney N., Sitzmann J.V., Cahill P.A., et al. Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis 2007, 195:e125-e133.
7. Hung C.F., Huang T.F., Chen B.H., Shieh J.M., Wu P.H., Wu W.B. Lycopene inhibits TNF-alpha-induced endothelial ICAM-1 expression and monocyte-endothelial adhesion. Eur J Pharmacol 2008, 586:275-282.
8. Hall A.J., Babish J.G., Darland G.K., Carroll B.J., Konda V.R., Lerman R.H., et al. Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry 2008, 69:1534-1547.
9. Tripp M.L., Konda V.R., Darland G., Desai A., Chang J., Carroll B.J., et al. Rho-iso-alpha acids and tetrahydro-iso-alpha acids are selective protein kinase inhibitors which potently reduce inflammation in macrophages in vitro and in the collagen-induced rheumatoid arthritis model in vivo. Acta Hortic 2009, 848:221-234. (ISHS) 848.
10. Desai A., Konda V.R., Darland G., Austin M., Prabhu K.S., Bland J.S., et al. META060 inhibits multiple kinases in the NF-kappaB pathway and suppresses LPS-mediated inflammation in vitro and ex vivo. Inflamm Res 2009, 58:229-234.
11. Konda V.R., Desai A., Darland G., Bland J.S., Tripp M.L. META060 inhibits osteoclastogenesis and MMPs in vitro, and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. Arthritis Rheum 2010, 62:1683-1692.
12. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005, 35:8-17.
13. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
14. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
15. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121:S21-S31.
16. Gosling J., Slaymaker S., Gu L., Tseng S., Zlot C.H., Young S.G., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773-778.
17. Makino Y., Cook D.N., Smithies O., Hwang O.Y., Neilson E.G., Turka L.A., et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol 2002, 102:302-309.
18. Veillard N.R., Kwak B., Pelli G., Mulhaupt F., James R.W., Proudfoot A.E., et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004, 94:253-261.
19. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
20. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
21. Gough P.J., Gomez I.G., Wille P.T., Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006, 116:59-69.
22. Fukuda D., Shimada K., Tanaka A., Kusuyama T., Yamashita H., Ehara S., et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006, 97:175-180.
23. Kadoglou N.P., Vrabas I.S., Sailer N., Kapelouzou A., Fotiadis G., Noussios G., et al. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab 2010, 36:144-151.
24. Kullich W.C., Mur E., Aglas F., Niksic F., Czerwenka C. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:155-160.
25. Unal R., Yao-Borengasser A., Varma V., Rasouli N., Labbate C., Kern P.A., et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab 2010, 95:2993-3001.
26. Ameyar M., Wisniewska M., Weitzman J.B. A role for AP-1 in apoptosis: the case for and against. Biochimie 2003, 85:747-752.
27. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973.
28. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
29. Ho T.Y., Yan W., Bagnell C.A. Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-kappaB pathway in human THP-1 cells. J Leukoc Biol 2007, 81:1303-1310.
30. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.